FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

The FDA approved a supplemental application for Lamictal (lamotrigine) filed by GlaxoSmithKline, leading to changes in the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Epilepsy

Drugs mentioned

• LAMICTAL (LAMOTRIGINE)

Snippet

SUPPL AP for LAMICTAL (LAMOTRIGINE)